GlassScriptPhysician profile
Shanda S Dixon
NPI 1225381767
$6,515.53
in general payments reported to CMS, 2019-2025
25 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,043 · 2022: $1,107 · 2023: $1,414 · 2024: $1,048 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.28 |
| Education | $505.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,643.04 | 2021-2025 | |
| Janssen Biotech, INC. | $1,020.14 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $765.59 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $489.41 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $387.87 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $284.06 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $279.57 | 2022-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $255.24 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $253.35 | 2021-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $221.10 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $198.85 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $147.74 | 2021-2025 | Opzelura |
| Ucb, INC. | $125.07 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $94.30 | 2023-2025 | Zoryve |
| Pfizer INC. | $73.82 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $61.00 | 2025 | Vyjuvek |
| Galderma Laboratories, L.P. | $50.47 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.38 | 2022-2025 | Spevigo |
| Organon LLC | $22.08 | 2024-2025 | Hadlima |
| Botanix Sb INC | $21.26 | 2025 | Sofdra |
| Genentech USA, INC. | $18.78 | 2021 | |
| Glaxosmithkline, LLC. | $17.15 | 2021 | |
| Organogenesis INC. | $15.28 | 2024 | |
| Dermavant Sciences, INC. | $15.07 | 2023 | Vtama |
| Reprise Biomedical, INC. | $11.91 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanda Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.